Bcl-2 inhibitors, such as the compound identified by the CAS number 383860-03-5, are a class of small molecules designed to target and inhibit the B-cell lymphoma 2 (Bcl-2) protein, which plays a crucial role in regulating apoptosis (programmed cell death). These inhibitors are particularly significant in cancer therapy, as Bcl-2 is often overexpressed in various malignancies, allowing cancer cells to evade apoptosis and survive longer than normal cells. The characteristics of Bcl-2 inhibitors typically include their ability to bind selectively to the Bcl-2 protein, disrupting its function and promoting the apoptotic pathway in cancer cells. This mechanism can lead to increased sensitivity of tumors to chemotherapy and other treatments. Additionally, these compounds may exhibit varying degrees of selectivity for different Bcl-2 family members, influencing their therapeutic efficacy and side effect profiles. Research continues to explore their potential in combination therapies and their role in overcoming resistance to existing cancer treatments.

Bcl-2 Inhibitor

383860-03-5: Bcl-2 inhibitors, such as the compound identified by the CAS number 383860-03-5, are a class of small molecules designed to target and inhibit the B-cell lymphoma 2 (Bcl-2) protein, which plays a crucial role in regulating apoptosis (programmed cell death). These inhibitors are particularly significant in cancer therapy, as Bcl-2 is often overexpressed in various malignancies, allowing cancer cells to evade apoptosis and survive longer than normal cells. The characteristics of Bcl-2 inhibitors typically include their ability to bind selectively to the Bcl-2 protein, disrupting its function and promoting the apoptotic pathway in cancer cells. This mechanism can lead to increased sensitivity of tumors to chemotherapy and other treatments. Additionally, these compounds may exhibit varying degrees of selectivity for different Bcl-2 family members, influencing their therapeutic efficacy and side effect profiles. Research continues to explore their potential in combination therapies and their role in overcoming resistance to existing cancer treatments.

<p>Bcl-2-IN-3 (Compound 10) is an inhibitor of Bcl-2, utilized in cancer research.</p>

CAS 383860-03-5

Bcl-2 Inhibitor

Bcl-2-IN-3

Ref: TM-T201232